Cytogenetic significance of chromosome 17 aberrations and P53 gene mutations as prognostic markers in oral squamous cell carcinoma

Walid Zedan1*, Mohamed I Mourad1, Sherin M Abd El-Aziz2, Nagla M Salamaa1 and Asem A Shalaby3

Abstract

Background: Cytogenetic analysis has detected an accumulation of genetic lesions in oral cancers. Numerical changes in chromosome 17 might be associated with an up-regulation of p53 gene, and could contribute to critical events in carcinogenesis. The aim of this study was to reveal possible correlations between the numerical aberrations of chromosome 17, deletion or amplification of the P53 gene and histological grading in patients with oral squamous cell carcinoma (OSCC).

Methods: This study was performed retrospectively on anonymous forty paraffin embedded specimens diagnosed with a primary OSCC. Sections were prepared for p53 immunohistochemical staining and FISH technique evaluation.

Results: All studied cases showed a positive nuclear staining with different indices for the p53 protein. Furthermore, statistical analysis showed a significant difference between all histological types of OSCC. In term of P53 immunoreactivity well differentiated OSCC showed the highest, whereas poorly differentiated showed weakest. Regarding chromosome 17 aberrations and p53 gene mutations, Spearman correlation test revealed a statistical significant positive correlation between chromosome 17 abnormalities and p53 gene mutations as well as with the immunohistochemical expression of p53 proteins. Moreover, the positive association between p53 gene mutations and the expression of p53 protein was statistically significant.

Conclusion: In the light of the previous findings, we concluded that numerical aberrations of chromosome 17 and p53 gene mutations as well as expression of p53 protein have enormous influence on various cellular processes including differentiation and carcinogenesis. Such knowledge provides an easy and simplified approach to prognosis predilection for OSCC.

Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2015_232.

Keywords: Oral squamous cell carcinoma, P53 gene, P53 immunoreactivity, Chromosome 17, FISH technique

Background

The development of oral squamous cell carcinoma (OSCC) depends on both environmental and genetic factors. Most oral cancer cases have had prolonged exposure to tobacco and alcohol, but these carcinogens cannot fully account for the development of cancers in these individuals [1]. Numerous studies have shown that tobacco causes damage of the cell DNA and alcohol reduces the effectiveness of DNA repairing that would be needed [2]. The accumulations of genetic abnormalities in carcinogenesis are divided into four phases: initiation, promotion, conversion and progression [3]. Cytogenetic analysis has detected an accumulation of genetic lesions in oral cancers [4]. Numerical changes in chromosomes 7 and 17 might be associated with an up-regulation of p53 gene, and could contribute to critical events in laryngeal carcinogenesis [4]. Moreover, human papillomavirus-associated oropharyngeal carcinoma (HPV-associated oropharyngeal
The development and progression of human tumors often involves inactivation of tumor suppressor gene function [12]. The P53 gene, located on the short arm of chromosome 17p13, consists of 11 exons coding for a nuclear phosphoprotein, which can bind to specific DNA sequences acting as a transcription factor. Dysfunction in the P53 tumor suppressor gene is involved in the etiopathogenicity of OSCC [4]. The exact role of the p53 genetic alterations in different stages of the tumorigenic process is not completely established. The p53 gene has the capacity to induce repair of the damaged DNA by activating repair proteins and by stopping the cell cycle at the G/S regulation point, arresting growth of the cells. Another anti-cancer role of P53 is initiating apoptosis of a cell with irreparable DNA damage [13].

The aim of this study was to identify numerical aberrations of chromosome 17, deletion or amplification of P53 gene and to reveal possible correlations between these abnormalities and histological grading in patients with OSCC to be used as an easy and simplified prognostic marker.

Methods

This study was performed retrospectively on forty anonymous paraffin embedded blocks diagnosed with a primary OSCC and clinical data were obtained without any personal information on those cases from the archives of faculty of Dentistry, Oral Pathology Department and the Oncology center of Mansoura University, Egypt between the years 2010 and 2013. Tumor samples were processed by usual techniques for inclusion in paraffin in the pathology lab of faculty of Medicine, Mansoura University. 3 micrometer-thick sections from the paraffin blocks were stained with hematoxylin-eosin for the establishment of the histopathological type and differentiation stage, based on the WHO International Classification of Diseases for Oncology (1990). Clinical staging was performed using the TNM Staging. Additional sections were prepared for immunohistochemical analysis and FISH technique evaluation. Five normal control slides obtained from mucosal specimens of non-oral cancer patients for this comparative study. Details of the cases are given in Table 1.

p53 immunohistochemistry

The sections were deparaffinized in xylene and rehydrated in alcohol. Endogenous peroxidase activity was quenched by immersion in a 1:4 solution of 3% hydrogen peroxide in methanol for 20 min, followed by rinsing several times in Tris-buffered saline (TBS). Slides were placed in Coplin jars containing a 1:10 solution of target retrieval solution (Target Retrieval Solution 10×, pH9.0, Dako Cytomation S2367, Glostrup, Denmark) in distilled water and heated in a water bath at 98°C for 20 min to unmask the antigen. After the heating steps, the jars were allowed to cool for 30 min. Nonspecific binding was blocked by incubation with 5% bovine serum albumin (BSA) in TBS for 30 min at room temperature, the slides were incubated with the primary anti-P53 at a dilution of 1:200 in antibody diluent (Antibody diluent, Dako Cytomation) overnight at room temperature in a moist chamber. The slides were rinsed in TBS (3 times for 10 min each) and then incubated with secondary antibody (EnVision detection Kit Peroxidase/DAB Rabbit/mouse, Dako Cytomation) according to the manufacturer’s instructions. The slides were rinsed in TBS (3 times for 10 min each) and then stained with 3,3′-diaminobenzidinetetrahydrochloride (EnVision detection Kit Peroxidase/DAB Rabbit/mouse, Dako Cytomation).

Table 1 Clinicopathological variables of studied cases

| Patients characteristics | Number | (%) |
|--------------------------|--------|-----|
| **Age**                  |        |     |
| <=40 years               | 8      | 20% |
| >40 years                | 32     | 80% |
| **Sex**                  |        |     |
| Male                     | 28     | 70% |
| Female                   | 12     | 30% |
| **Site**                 |        |     |
| Tongue                   | 16     | 40% |
| Lip                      | 4      | 10% |
| Palate                   | 12     | 30% |
| Cheek                    | 8      | 20% |
| **Clinical staging**     |        |     |
| (TNM grading system)     |        |     |
| Stage I                  | 4      | 10% |
| Stage II                 | 8      | 20% |
| Stage III                | 16     | 40% |
| Stage IV                 | 12     | 30% |
| **Histological grade**   |        |     |
| Well differentiated      | 20     | 50% |
| Keratinizing moderately differentiated | 8     | 20% |
| Non-keratinizing moderately differentiated | 4     | 10% |
| Poorly differentiated    | 8      | 20% |
Sections were counterstained with Mayer’s haematoxylin solution. Negative controls were run in parallel, replacing the primary antibody with antibody diluent. The immunoreactive protein was localized in cancer cell nuclei.

**Digital image analysis**

Slides were photographed using Olympus® digital camera installed on Olympus® microscope with 1/2 X photo adaptor, using 40 X objective. The images were analyzed on Intel® Core I3® based computer using VideoTest Morphology® software (Russia) with a specific built-in automated object counting routine for immunohistostain analysis. The immunoreactivity in the malignant cells in each section was graded according to the number of positively staining nuclei: ≤ 1% nuclei with a positive reaction are considered as a negative, > 1 ≤ 10% as low (+), >10% ≤ 50% as intermediate (++) and > 50% as high (+++).

**Interphase FISH analysis**

Interphase FISH technique was done on thin formalin- fixed paraffin- embedded material. Using the Olympus BX 61, fluorescent microscope equipped with appropriate filters suitable for Fluorescein, Rhodamine and DAPI which present in Oncology Center, Faculty of Medicine, Mansoura University. Representative images were captured via a monochrome digital camera using Cytovision Image Capture software (Applied Imaging).

**Technique**

Interphase FISH technique was performed on tissue sections after optimization of the protocol using commercially available probe from Vysis, locus specific identifier LSA TP53/CEP 17 FISH Probe Kit which is intended to detect the copy number of the LSI TP53 probe Spectrum Orange target located at chromosome 17p13.1 and of the CEP 17 (17p11.1-q11.1 Alpha Satellite) probe Spectrum Green Dual Colour target located at the centromere of chromosome 17 according manufacturer’s protocol Abbott/Vysis (Vysis, Downers Grove, IL, USA). Sections were deparaffinized in xylene (3 times each for 5 min) and dehydrated in ethanol (3 times each for 3 min). Sections were pre-treated by placing the slides in 1xHCL (hydrochloric acid) 0.1 M for 20 minutes to avoid tissue autofluorescence, then the slides were placed in 2X SSC (Standard Saline Citrate) wash in a coplin jar for 3 minutes. The slides were then heated in microwave at 99°C in 1 mM sodium citrate buffer (pH 6.0) for 60 min, followed by 3 min in distilled water, 20 min in pepsin solution (Sigma P8038) (0.05 mg/mL pepsin solution in N HCL 0.01 M) at 37°C followed by washing in distilled water for 3 min and dehydrating for 1 min in increasing concentrations of alcohol (70, 85 and 100%) after which they were air-dried. Then 20 ul of 50% formamide hybridization buffer was added to the marked area on the slide and incubated at 90°C for 20 min on the HyBrite™ machine (Olympus Life Science). After that five μl of probe solution were applied to each slide, overlaid with a coverslip, which was sealed with rubber cement. Slides were denatured for 5 min at 73°C and hybridized for at least 16 h at 37°C in a Vysis HyBrite™ machine. Following hybridization, the slides were washed with 2 × SSC/0.1% NP40 at room temperature for 5 min then at 73°C with 0.4 × SSC/0.3% NP40 for 2 min and again at room temperature with 2 × SSC/0.1% NP40 for 1 min. After air-drying in the dark, slides were counterstained with 10 μl of 4’6’-diamino-2-phenylindole (DAPI II). A cover slip was applied and sealed with nail varnish. The slides were analyzed Using the Olympus BX 61, fluorescent microscope (Olympus Life Science) equipped with appropriate filters suitable for Fluorescein, Rhodamine and DAPI. Representative images were captured via a monochrome digital camera using Cytovision Image Capture software (Applied Imaging).

![Figure 1](https://example.com/figure1.png)

**Figure 1** Shows the mean ± SD of P53 immunohistochemical expression in different histological grades of the studied SCC cases.
Interpretation of FISH results

The LSI P53 probe hybridizes to chromosome 17. The approximately 172 kb Spectrum Orange P53 probe contains the complete TP53 gene and is located at chromosome 17p13.1. The Spectrum Green CEP 17 probe is a control probe which hybridizes to the centromere region of chromosome 17p11.1-q11.1. All the patients’ subjects presented the numerical alterations in the chromosome 17 and the P53 gene. On hundred nuclei were scored under x100 magnification, using an oil immersion objective and the fluorescent microscope for each defined histological area from the tumor and tumor-adjacent epithelia, each nucleus being assessed for the chromosome copy number. The numerical aberrations of chromosome 17 varied from individual to individual. Specifically, only distinct isolated nuclei were counted. We interpreted as monosomy 17 if the mean number of green signals in analyzed cells for each subject was lower than two. Chromosome polysomy was defined as the fraction of the cells demonstrating three or more green signals in each nucleus. In normal cell, therefore there should be 2O2G signals. We interpreted as P53 gene deletion if there is one orange signal in analyzed cells for each subject. Multiplication in P53 gene was defined as demonstrating more than 2 orange signals in each

Figure 2 Well differentiated SCC revealed intense immunoreactivity for p53.

Figure 3 Poorly differentiated SCC showed mild p53 immunoreactivity.

Figure 4 Keratinizing moderately differentiated SCC revealed a moderate p53 immunopositivity.

Figure 5 Non-keratinizing moderately differentiated SCC showed moderate p53 immunoreactivity.
nucleus. In general according the control, cut off 5% was used.

**Statistical analysis**

Statistical analysis of the data was done by using Statistical Package for Social Science (SPSS) version 20.0. Qualitative variables were presented as number and percent. Quantitative variable were presented as mean ± SD. Kendall’s tau-b correlation was used to assess relations between variables. Significance was considered when $P$ value < 0.05.

**Results**

This study included forty cases of OSCC with a high tendency for occurrence in old male patients (all of the males were smokers). Most of the cases were outdoor workers (farmers & street vendors). All the tumors were intraoral and the tongue was the most common site (40%). In relation to the TNM staging system, majority of cases were stage III and stage IV respectively (40%, 30%). Among the histological grades, well differentiated type was the most frequent (50% of all studied cases) (Table 1).

Immunohistochemically, all studied cases showed a positive nuclear staining for the p53 protein with different indices (Figure 1). Well differentiated form of SCC showed the highest extent of p53 immunoreactivity (mean ± standard deviation (SD) = 74.40 ± 3.22) (Figure 2), whereas poorly differentiated cases showed lowest immunopositivity for p53 (mean ± SD = 7.00 ± 1.69) (Figure 3).

In moderately differentiated SCC cases, the tumor staining for p53 was intermediate but with different extents in keratinizing and none keratinizing subtypes. The keratinizing moderately differentiated variant revealed a higher level of p53 immunoreactivity (mean ± SD = 60.00 ± 4.07) (Figure 4) than the non-keratinizing subtype (mean ± SD = 32.00 ± 1.15) (Figure 5). Statistical analysis of these findings showed a significant difference between all histological types of OSCC in relation to the immunohistochemical expression of p53 protein (Table 2).

In the present study as shown in Tables 3 and 4; 28 subjects (70%) with chromosome 17 trisomy and only 8 subjects (20%) with chromosome 17 monosomy (Figures 6 and 7) were detected. Cases with chromosome 17 trisomy presented p53 gene amplification or multiplication while the cases with chromosome 17 monosomy revealed p53 gene deletion (Figures 6 and 7). All well differentiated SCC cases as well as the keratinizing moderately differentiated SCC type showed chromosome 17 and p53 gene amplification or duplication. On the opposite side, all poorly differentiated SCC cases exhibited chromosome 17 and p53 gene deletion (Figure 6). The non-keratinizing moderately differentiated variant presented a striking finding. They revealed p53 gene deletion while the chromosome 17 was normal (Figures 6 and 8).

The Spearman correlation test revealed a statistical significant positive correlation between chromosome 17 abnormalities and p53 gene mutations as well as with the immunohistochemical expression of p53 proteins.

### Table 2 Shows the mean ± SD of P53 immunohistochemical expression in different histological grades of the studied SCC cases (ANOVA)

| Comparison                  | Well diff. SCC | Keratinizing moderately diff. SCC | Non-keratinizing moderately diff. SCC | Poorly diff. SCC | ANOVA P value |
|-----------------------------|----------------|----------------------------------|---------------------------------------|------------------|---------------|
| Mean ± SD                   | 74.40 ± 3.22   | 60.00 ± 4.07                     | 32.00 ± 1.15                          | 7.00 ± 1.69      | 0.000         |
| P1                          | 0.000          | 0.000                            | 0.000                                 | 0.000            |               |
| P2                          | 0.000          | 0.000                            |                                       | 0.000            |               |
| P3                          |                |                                  |                                       |                  |               |

All results are expressed as mean ± SD.
Non significant: at $P$ >0.05.
Significant: at $P < 0.05$.
P1 = significance between Well differentiated SCC group and other groups.
P2 = significance between Keratinizing moderately differentiated SCC and other groups.
P3 = significance between Non Keratinizing moderately differentiated SCC and Poorly differentiated SCC.

### Table 3 The mean number of signals for chromosome 17 abnormalities and p53 gene mutations in different histological grades of the studied SCC cases

| Grade                        | Number (total = 20) | Mean number of signals |
|------------------------------|---------------------|------------------------|
|                              |                     | Chromosome 17 abnormalities | P53 gene mutation |
| Well differentiated SCC       | 20                  | 3                      | 3 |
| Keratinizing moderately diff. | 8                   | 3                      | 3 |
| Non-keratinizing moderately  | 4                   | 2                      | 1 |
| Poorly differentiated SCC     | 8                   | 1                      | 1 |
Moreover, the positive association between p53 gene mutations and the expression of p53 protein was statistically significant \( (P = .000) \) (Table 5).

**Discussion**

Universally, it is accepted now that alterations in multiple oncogenes and tumor suppressor genes are the genetic basis for human carcinogenesis [12]. The p53 gene is the most frequent target of genetic alterations, being mutated in half of human cancers [13]. The p53 mutation usually shows clonality in cancer, therefore it has occurred in the early stage of carcinogenesis, as in OSCC [14]. A very recent research used low copy number of mitochondrial DNA (mtDNA) to predict worse prognosis in early-stage laryngeal cancer patients [15]. So far, prognosis prediction will be the focus of cancer researchers for the assurance of saving cancer patients lives.

In the present study, \( (40\%) \) of the OSCC cases were found in the tongue. This is the same as compared to most of the other studies [16,17]. Moreover, it was found that \( (80\%) \) of the cases were in the 40 year or above age group \( (n = 32) \). Overall male: female ratio of about 2.33:1. This is in accordance with other studies, as reported by Idris et al. and Sugarman et al. [18,19].

According to Llewellyn et al. [20], SCC is not so frequent in young patients. Only 1% to 6% of SCC cases occur in patients under the age of forty indicating that the occurrence in children and adolescent was extremely rare [20,21]. Surprisingly, in our study, patients under 40 years of age were reported as \( (20\%) \) \( (n = 8) \). This shows that the incidence of oral cancer among young patients has markedly increased in our country. From our results most of the patients were exposed to sun light and male patients were smokers the previous information's are in

| Comparison | Well differentiated SCC (No & %) | Keratinizing moderately differentiated SCC (No & %) | Non keratinizing moderately differentiated SCC (No & %) | Poorly differentiated SCC (No & %) |
|------------|--------------------------------|---------------------------------|---------------------------------|-----------------|
| Multiplication | Chromosome 17 | 20 (100%) | 8 (100%) | 0 | 0 |
| | P53 gene | 20 (100%) | 8 (100%) | 0 | 0 |
| Normal | Chromosome 17 | 0 | 0 | 4 (100%) | 0 |
| | P53 gene | 0 | 0 | 0 | 0 |
| Deletion | Chromosome 17 | 0 | 0 | 0 | 8 (100%) |
| | P53 gene | 0 | 0 | 4 (100%) | 8 (100%) |
| Total number | 20 | 8 | 4 | 8 |

(P = .000). Moreover, the positive association between p53 gene mutations and the expression of p53 protein was statistically significant \( (P = .000) \) (Table 5).
accordance with the carcinogenic effect of these two factors [20]. Finally, these results may be also due to the increase of nutritional deficiencies, pesticides pollution and drugs addictions in youngster.

Regarding TNM staging of SCC, most of patients presented in stage III (40%) and stage IV (30%), respectively. This is almost the same as described by HAQ M et al. [17]. This indicates that SCC in our country is detected or diagnosed mostly in advanced stages which were in contrast to Manuel et al. and Okada et al. who showed presentation of the cases at their early stages [22,23]. This might be due to the fact of high illiteracy rate, ignorance about the disease and poor referral system in our country. In addition, Shah et al., 2010 reported that oral cancers are diagnosed late (Stage III and IV) in Pakistan and need immediate public and professional attention [24].

Well differentiated was the most common histopathological type of OSCC in our study. This finding is in contrast to Haq M et al., whom found that poorly differentiated SCC was the most prevalent histological variant [17]. In accordance with the findings of our study, Valerie et al. reported that poorly differentiated subtype of SCC occurs much less commonly than well differentiated variant [25,26].

In the present study, it was found that a positive nuclear staining for the p53 protein with different indices in all studied cases. This finding is in agreement with Bai L, Zhu W-G 2006, whom suggested that p53gene is known to play a key role in all types of human cancers [27]. This could be attributed to the significant involvement of p53 gene in oncogenesis as p53 gene plays a pivotal role in regulation of the cell cycle and induction of apoptosis. In addition, it were noticed that the characteristic feature of the p53 gene mutational map is the high frequency of missense point mutations. Unlike many other tumor suppressor genes, more than 80% of p53 gene mutations result in single amino-acid substitutions which lead to the synthesis of a stable full-length protein rather than deletions. These missense mutations lead to the synthesis of a protein that lacks specific DNA binding site and accumulates in the nucleus of tumor cells [28]. Furthermore, it was found that p53 gene to be overexpressed in 63% of oral carcinomas [3]. From the previous finding we can hypothesize that accumulation of the P53 protein in an inactive form might has a role in the development of OSCC. There is now strong evidence that mutation not only abrogates p53 tumor-suppressive functions, but in some instances can also endow the mutant proteins with novel activities. Such neomorphic p53 proteins are capable of dramatically altering tumor cell behavior, primarily through their interactions with other cellular proteins and regulation of cancer cell transcriptional programs [29].

An interesting observation was noted in the present study that highly differentiated tumors had a high p53 immunostaining whilst poorly differentiated showed a significantly weaker immunohistochemical expression of p53 compared with well differentiated form. These results are consistent with other studies which have demonstrated that; statistically significant co-relation was seen between the histological grade and p53 gene overexpression. Also, histological parameters which indicated high cellular turnover were also significantly associated with p53 gene overexpression [30]. This might be interpreted as most of the mutations in the poorly OSSC is truncating mutations (deletions) which may lead to less P53 protein production and absence of its reactivity in the nucleus which in turn indicating

Table 5 Shows the Spearman correlations between chromosome 17 abnormalities, P53 gene mutations and immunohistochemical expression of P53 protein in different histological types of the studied SCC cases

| Comparison          | Chromosome 17 abnormalities | P53 gene mutations | Immunohistochemical expression of P53 protein |
|---------------------|----------------------------|--------------------|---------------------------------------------|
| chromosome 17       | r 1.000                    | .988               | .794                                        |
| abnormalities       | P value .000               | .000               | .000                                        |
| P53 gene mutations  | r .988                     | 1.000              | .784                                        |
| P value .000        |                            | .000               | .000                                        |

Significant : at P < 0.05.
the aggressive nature of the poorly differentiated tumo [31-33].

In our study, a statistical significant positive correla-
tion was found between chromosome 17 abnormalities and p53 gene mutations. Cases with chromosome 17 tri-
somy presented p53 gene amplification or multiplication while the cases with chromosome 17 monosomy re-
vealed p53 gene deletion. Furthermore, keratinizing SCC cases exhibited amplification of chromosome 17 and p53 gene while poorly differentiated exhibited chromosome 17 and p53 gene deletions. Interestingly, mutations in the p53 gene occur at different phases of the multistep process of malignant transformation [34]. In accordance, Kozomara et al. mentioned that p53 deletions are associ-
ated with a higher risk of relapse and contribute to an even worse prognosis of patients with OSCC [35]. More-
over, numerical changes in chromosomes 17 might be associated with an up-regulation of p53 genes, and could contribute to critical events in laryngeal carcinogenesis [4]. Other data from literature revealed that the fre-
quency of cells with polysomy increased with histological progression suggesting that the biological factors might influence the rate of accumulation of genetic hits. Gen-
omic instability may also lead to chromosome non-
disjunction and to the generation of cells with zero, one, two, and three or more chromosome copies [36]. Also, altered p53 gene expression in premalignant les-
sions is associated with increased chromosomal polys-
omy [3]. Hence, the presence of cells exhibiting three or more chromosome copies (chromosome polysomy) might be considered a quantitative marker of ongoing or accumulated genomic instability in tumors [37,38].

This study revealed a statistical significant positive cor-
relation between chromosome 17 abnormalities and the immunohistochemical expression of p53 proteins. Other previously reported findings suggest that a statistically significant correlation existed between p53 protein expression and polysomy 17 [36,39,40]. Furthermore, p53 protein overexpression was associated with the fre-
quency of p53 mutations in tumor tissue, while p53 muta-
tions, particularly missense and nonsense mutations might have some impact on survival rate [39]. This could be explained by Fritsche et al. who indicated that wild type p53 activation involves an increase in overall p53 protein level as well as qualitative changes in the protein through extensive post-translational modification, thus resulting in activation of p53-targeted genes [41]. Moreover, the immunohistochemically detectable high p53 gene expression levels reflect the increased half-life of the protein encoded by a mutated gene [42,43]. Also, Busby-Earle et al. concluded that somatic mutation in the hotspot regions of the p53 gene occurs infrequently in cervical carcinomas; that immunocyto-
chemically detectable levels of p53 are also infrequent [44]. Upon these results, it is assumed that polysomy in chromosome 17 correlates with the mutation of p53 gene which results in an accumulation of aberrant p53 protein.

Conclusion
In the light of the current study findings, we found that numerical aberrations of chromosome 17, p53 gene mu-
tations as well as expression of p53 protein have massive influence on various cellular processes including differ-
entiation and carcinogenesis as mutant p53 can induce an increased epigenetic instability of tumor cells, facili-
tating and accelerating the evolution of the tumor. From our results, we conclude that bad prognosis (aggressive tumors) is directly correlated with chromosome 17 aber-
rations and P53 deletion mutation. Finally, such know-
ledge provides an easy and simplified approach to prognosis predilection for OSCC.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Study design and study concepts (WZ, MM, NS). Data acquisition & samples collection (MM, SA, AS). Laboratory work (SA, MM, AS, NS, WZ). Data analysis (SA, MM, AS, NS). Manuscript preparation, editing and reviewing (WZ, MM, SA). All authors read and approved the final manuscript.

Author details
1 Department of Oral and maxillofacial Pathology, Faculty of Dentistry, Mansoura University, Mansoura, Egypt. 2 Department of Clinical Pathology-Hematology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 3 Department of General Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Received: 13 April 2014 Accepted: 18 December 2014
Published online: 22 February 2015

References
1. Charlotte J, Yuehsheng J, Johan W, Jan Å, Michael D, Fredrik M. Karyotypic heterogeneity and clonal evolution in squamous cell carcinomas of the head and neck. Cancer Genet Cytogenet. 2002;122(2):85–96.
2. Subramanian S, Sankaranarayanan R, Bapat B, Somnathan T, Thomas G, Mathew B, et al. Cost-effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India. Bull World Health Organ. 2009;87:200–6. Acha-Sagredo, A.
3. Ruesga M, Rodriguez C, Aguirregaviria J, Pancorbo M, Califano J, Aguirre J. p53 mutation is rare in oral mucosa brushings from patients previously treated for a head and neck squamous cell carcinoma. Oral Oncol. 2009;45(8):662.
4. Choi G, Chung K. Polysomies of chromosome 7 and 17 in head and neck squamous cell carcinoma. Arch Otolaryngeal Head Neck Surg. 1996;122:1062–7.
5. Fujimaki M, Fukumura Y, Mitani K, Kurisaki A, Yokoyama J, Ikeeda K, et al. Histological subtypes and characteristic structures of HPV-associated oropharyngeal carcinoma; study with Japanese cases. Diagn Pathol. 2013;8:211.
6. Ngiro JM, Baker SJ, Presilinger AC. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1988;342:705–7.
7. Lane DP, Benchimal S. P53: oncogene or anti-oncogene. Genes Dev. 1990;4:1–8.
8. Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, et al. Genetic alterations of chromosome 17 in human breast carcinoma studied by fluorescence in situ hybridization and molecular DNA techniques. Breast Cancer Res. 2005;7:267–73.
9. Hopman AH, Voorber CE, Ramaekers FC. Detection of genomic changes in cancer by in situ hybridization. Mol Biol Reports. J. 1994;19:31–44.
10. Fadl-Elmu, I. Chromosomal changes in uroepithelial carcinomas. Cell Chromosome 2005; doi: 10.1186/1475-9268-4:1, 4: 1.
11. Papavasileiou D, Tosios K, Christopoulos P, Goutas N, Vlahodimitropoulos D. Her-2 Immunohistochemical Expression in Oral Squamous Cell Carcinomas is Associated with Polymorphism of Chromosome 17, Not Her-2 Amplification. Head Neck Pathol. 2009;3(4):263–70.
12. Weinberg RA. Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis. Cancer Res. 1988;49(4):1538–7445.
13. Meszaros N, Belengeanu D, Stoica D, Andreescu N, Farcaş Ş, Stoian M, et al. Analyses of numerical aberrations of chromosome 17 and tp53 gene deletion/amplification in human oral squamous cell carcinoma using dual-color fluorescence in situ hybridization. Tom. 2010;XVII / 1:142–6.
14. Kashwazaki H, Tonoki H, Tada M, Chiba I, Shindo M, Touska Y, et al. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene. 1997;15(22):2667–74.
15. Ding S, Qu Y, Wei J, Shao Y, Yang Q, Ji M, et al. Low copy number of mitochondria DNA (mtDNA) predicts worse prognosis in early-stage laryngeal cancer patients. Dangin Pathol. 2014:9:28.
16. Chen AY, Myers NC. Cancer of the oral cavity. Dis Mon. 2001;47:275–361.
17. Haq MEU, Abdul H, HaniF MK, Warrain RA, Mahmood HS, Saddique K. Frequency and Pattern of Oral and Maxillo-facial Carcinomas. J Oral and Maxillofacial Res. Ann. 2005;15(4):171–4.
18. Idri AM, Ahmed HM, Mukhtar B, Gadir AF, El-Beshie EI. Descriptive epidemiology of oral neoplasms in Sudan 1970–1980 and the role of tobacco. Int J Cancer. 1995;61:155–8.
19. Sugarman PB, Savage NW. Oral cancer in Australia: 1983–1996. Aust Dent J. 2002;47:45–6.
20. Llewellyn CD, Johnson NW, Warrakulasuriya KAA. Risk factors for squamous cell carcinoma of the oral cavity in young people—a comprehensive literature review. Oral Oncol. 2001;37:401–18.
21. Torossian JM, Baziat JL, Philip T, Bejui FT. Squamous cell carcinoma of the oral cavity in young people—a comprehensive literature review. Oral Oncol. 2001;37:401–18.
22. Manuel S, Raghavan SKN, Pandey M, Sebastian P. Survival in patients under 45 years with squamous cell carcinoma of the oral cavity. J Oral Maxillofac Surg. 2003;32:167–73.
23. Okada Y, Mataga I, Kagitari M, Ishii K. An analysis of cervical lymph nodes metastasis in oral squamous cell carcinoma: Relationship between grade of histopathology malignancy and lymph nodes metastasis. Int J Oral Maxillofac Surg. 2003;32:284–8.
24. Shah I, Selvar O, Luymman U, Ibrahim W, Mehmood S, Alamgir W. Clinical stage of oral cancer patients at the time of initial diagnosis. J Ayub Med Coll Abbottabad. 2010;22(3):1–3.
25. Valerie KY, Stephen EM, Robert GP. Histopathological Variants of Cutaneous Squamous Carcinoma. A Review. J. Skin Cancer. 2011; 210813.
26. Miyagi J, Tsuchako K, Kinjo T, Iwasa T, Hiyasa T, Recent striking changes in histological differentiation and rate of human papillomavirus infection in squamous cell carcinoma of the lung in Okinawa, a sub-tropical island in southern Japan. J Clin Pathol. 2000;53:676–84.
27. Bai L, Zhu W-G. p53: Structure, Function and Therapeutic Applications. J Cancer Mol. 2002;4(4):141–53.
28. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53.
29. Freed-poster WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–86.
30. Jayade BV, Bhat K, Paille BR, Nayak R, Sant A. Histological significance of p53 gene expression in squamous cell carcinoma of the buccal mucosa. J Maxillofacial and Oral Surg. 2009;8(3):205–10.
31. Muller PAJ, Vouwen KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2–8.
32. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.
33. Vouwen KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002;2:594–604.
34. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011;2(4):466–74.
35. Kozomara RJ, Brankovic-Magic MV, Jovic NR, Stosic SM, Magic ZM. Prognostic significance of TP53 mutations in oral squamous cell carcinoma with human papilloma virus infection. Int J Biol Markers. 2007;22(4):252–7.
36. Elango JK, Gangadharan P, Sumithra S, Kuriakose M. Trends of head and neck cancers in urban and rural India. Asian Pacific J Cancer Prev. 2006;7:108–12.
37. Stoica D, Andreescu N, Belengeanu A, Meszaros N, Cornianu M. Assessment of p53 and HER-2/neu genes status and protein products in oral squamous cell carcinomas. Rom J Morphol Embryol. 2013;54(4):1107–13.
38. Kamekawa A, Tsuji T, Oga A, Sasaki K, Shinozaki F. Chromosome 17 abnormalities in squamous cell carcinoma of the oral cavity, and its relationship with p53 and Bcl-2 expression. Anticancer Res. 1999;19:81–6.
39. Rossner Jr P, Gammon MD, Zhang Y-J, Terry MB, Hibshoosh H, Memeo L, et al. Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med. 2009;13(8):3847–57.
40. Li X, Tsuji T, Wen S, Mimura Y, Sasaki K, Shinozaki F. Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression. Cancer. 1997;79(12):2314–9.
41. Fritsche M, Haesler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 1993;8:307–18.
42. Bosari S, Viale G. The clinical significance of p53 aberrations in human tumors. Virchows Arch. 1995;427:229–41.
43. Gannon JV, Greaves R, Igglo R, Lane DP. Activating mutations in p53 produces a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J. 1990;9:1595–602.
44. Busby-Earle RMC, Steel CM, Williams ARW, Cohen B, Bird CC. p53 mutations in cervical carcinogenesis - low frequency and lack of correlation with human papillomavirus status. Br J Cancer. 1994;69:732–7.